ES2924257T3 - Métodos de tratar trastornos hepáticos o trastornos lipídicos con un agonista de THR-beta - Google Patents

Métodos de tratar trastornos hepáticos o trastornos lipídicos con un agonista de THR-beta Download PDF

Info

Publication number
ES2924257T3
ES2924257T3 ES17804979T ES17804979T ES2924257T3 ES 2924257 T3 ES2924257 T3 ES 2924257T3 ES 17804979 T ES17804979 T ES 17804979T ES 17804979 T ES17804979 T ES 17804979T ES 2924257 T3 ES2924257 T3 ES 2924257T3
Authority
ES
Spain
Prior art keywords
compound
subject
dose
test
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17804979T
Other languages
English (en)
Spanish (es)
Inventor
Rebecca Taub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madrigal Pharmaceuticals Inc
Original Assignee
Madrigal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc filed Critical Madrigal Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2924257T3 publication Critical patent/ES2924257T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES17804979T 2016-10-18 2017-10-18 Métodos de tratar trastornos hepáticos o trastornos lipídicos con un agonista de THR-beta Active ES2924257T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409833P 2016-10-18 2016-10-18
US201762516594P 2017-06-07 2017-06-07
PCT/US2017/057203 WO2018075650A1 (en) 2016-10-18 2017-10-18 Methods of treating liver disorders or lipid disorders with a thr-beta agonist

Publications (1)

Publication Number Publication Date
ES2924257T3 true ES2924257T3 (es) 2022-10-05

Family

ID=60480362

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17804979T Active ES2924257T3 (es) 2016-10-18 2017-10-18 Métodos de tratar trastornos hepáticos o trastornos lipídicos con un agonista de THR-beta

Country Status (12)

Country Link
US (3) US11090308B2 (cg-RX-API-DMAC10.html)
EP (2) EP3528817B1 (cg-RX-API-DMAC10.html)
JP (3) JP2019533019A (cg-RX-API-DMAC10.html)
KR (2) KR20230156159A (cg-RX-API-DMAC10.html)
CN (1) CN110167557A (cg-RX-API-DMAC10.html)
AU (1) AU2017346871B2 (cg-RX-API-DMAC10.html)
CA (1) CA3040888A1 (cg-RX-API-DMAC10.html)
DK (1) DK3528817T3 (cg-RX-API-DMAC10.html)
ES (1) ES2924257T3 (cg-RX-API-DMAC10.html)
IL (2) IL302336B2 (cg-RX-API-DMAC10.html)
MX (1) MX394463B (cg-RX-API-DMAC10.html)
WO (1) WO2018075650A1 (cg-RX-API-DMAC10.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2795450T3 (es) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
ES3029158T3 (en) * 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
US20210292304A1 (en) * 2018-06-22 2021-09-23 Hinova Pharmaceuticals Inc. Deuterated mgl-3196 compound and use thereof
TW202615431A (zh) * 2018-07-02 2026-04-16 美商瑪德瑞高製藥公司 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式
CA3111025C (en) 2018-09-06 2023-10-31 Galmed Research And Development Ltd Combination therapy for the treatment of liver disease
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
KR102692309B1 (ko) * 2019-01-15 2024-08-07 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
WO2020172075A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
CN119431265A (zh) 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) * 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CA3158379A1 (en) * 2019-11-26 2021-06-03 Hejun Lv 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof
CN111562321B (zh) * 2020-04-16 2022-10-28 广东省结核病控制中心 用于检测活动性肺结核的粪便代谢物及其检测系统
KR20230066408A (ko) * 2020-09-10 2023-05-15 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 레스메티롬의 결정형, 이의 제조 방법 및 이의 용도
US12616701B2 (en) 2020-10-19 2026-05-05 Assia Chemical Industries Ltd Solid state forms of Resmetirom
WO2022165227A1 (en) * 2021-02-01 2022-08-04 Madrigal Pharmaceuticals, Inc. Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders
US20250000836A1 (en) * 2021-07-21 2025-01-02 Cyta Therapeutics, Inc. Particle delivery of thyroid hormone receptor agonists and antagonists
TW202337470A (zh) 2021-09-27 2023-10-01 美商瑪德瑞高製藥公司 用於縮減肝臟體積之瑞美替隆
MX2024005647A (es) * 2021-11-11 2024-05-24 Terns Pharmaceuticals Inc Tratamiento de trastornos hepaticos con un agonista del thr-\03b2.
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
JP2026521649A (ja) * 2023-06-22 2026-06-30 マドリガル ファーマシューティカルズ インコーポレイテッド THR-βアゴニストを用いて肝障害を治療するためのバイオマーカーおよび関連する使用
WO2025011259A1 (zh) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 瑞司美替罗的晶型及其制备方法和用途
EP4762048A2 (en) 2023-10-16 2026-06-24 Cipla Limited Resmetirom polymorphs and process for their preparation
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025245216A1 (en) * 2024-05-22 2025-11-27 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-beta agonist
WO2026074443A1 (en) 2024-10-01 2026-04-09 Assia Chemical Industries Ltd. Solid state forms of resmetirom
CN121648128B (zh) * 2026-02-03 2026-06-30 华中科技大学同济医学院附属同济医院 特拉唑嗪或其药学上可接受的盐在制备用于预防和/或治疗肝纤维化的药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5615272A (en) 1979-07-17 1981-02-14 Ishihara Sangyo Kaisha Ltd N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
US7807647B2 (en) 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
US20050287667A1 (en) 2004-06-01 2005-12-29 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
ATE480524T1 (de) 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
ES2351274T3 (es) 2007-06-06 2011-02-02 Torrent Pharmaceuticals Ltd Nuevos compuestos.
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
ES2795450T3 (es) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
US8858502B2 (en) 2012-10-10 2014-10-14 Alcon Research, Ltd. Systems and methods for external pressure sensing
WO2015123256A1 (en) * 2014-02-14 2015-08-20 Cempra Pharmaceuticals, Inc. Compositions and methods for treating diabetes and liver diseases
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
TW202615431A (zh) 2018-07-02 2026-04-16 美商瑪德瑞高製藥公司 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式

Also Published As

Publication number Publication date
AU2017346871A1 (en) 2019-05-02
MX394463B (es) 2025-03-19
US20210330675A1 (en) 2021-10-28
EP3528817B1 (en) 2022-05-25
KR20190109387A (ko) 2019-09-25
US20240156826A1 (en) 2024-05-16
EP4112056A1 (en) 2023-01-04
IL266054A (en) 2019-06-30
MX2019004492A (es) 2019-11-18
JP2024001055A (ja) 2024-01-09
EP4112056B1 (en) 2026-01-21
US11806353B2 (en) 2023-11-07
JP2019533019A (ja) 2019-11-14
WO2018075650A1 (en) 2018-04-26
US11090308B2 (en) 2021-08-17
EP3528817A1 (en) 2019-08-28
US20200230146A1 (en) 2020-07-23
CN110167557A (zh) 2019-08-23
JP2025122012A (ja) 2025-08-20
IL302336A (en) 2023-06-01
AU2017346871B2 (en) 2023-08-03
IL302336B2 (en) 2025-11-01
IL266054B1 (en) 2023-06-01
KR20230156159A (ko) 2023-11-13
DK3528817T3 (da) 2022-08-08
CA3040888A1 (en) 2018-04-26
IL266054B2 (en) 2023-10-01
IL302336B1 (en) 2025-07-01

Similar Documents

Publication Publication Date Title
US11806353B2 (en) Methods of treating liver disorders or lipid disorders with a THR-beta agonist
US20200339591A1 (en) Compositions and methods of treatment for neurological disorders comprising a dementia
CN104507488A (zh) 乙型肝炎病毒cccDNA转录的调控
Dohil et al. Twice-daily cysteamine bitartrate therapy for children with cystinosis
ES2991090T3 (es) Inhibidores de KDM4
JP2019533019A5 (cg-RX-API-DMAC10.html)
US10894035B2 (en) Use of indole compounds to stimulate the immune system
Wenzel et al. Organic cation transporter 1 an intestinal uptake transporter: fact or fiction?
Xu et al. E17241 as a novel ABCA1 (ATP-binding cassette transporter A1) upregulator ameliorates atherosclerosis in mice
US20150099270A1 (en) Method of screening pharmaceuticals for drug interactions and nephrotoxicity
Liu et al. Pharmacological inhibition of the cysteine protease cathepsin C improves graft function after heart transplantation in rats
US12521415B2 (en) Accelerating repair of mucosal injury using gold(III) compounds
WO2021183691A1 (en) Combined inhibition of egfr and nrf2 in the treatment of malignant glioma
CN119499255A (zh) 一种化合物在治疗肝病中的应用
Lu et al. Structure-Based Discovery of Quinazolin-2-amine Derivatives as Potent ROR1 Pseudokinase Inhibitors with In Vitro and In Vivo Efficacy against Triple-Negative Breast Cancer
RU2480200C2 (ru) Внутрипузырное введение апазиквона после трансуретральной резекции при лечении рака
JP2010510238A (ja) γ線被曝に対する放射線防護および治療の方法
US10208028B1 (en) Methods of treating cancer
Wenzel et al. Organic Cation Transporter 1 an Intestinal Uptake Transporter: Fact
US20110082087A1 (en) Compounds for treating pain
Wenzel et al. Organic Cation Transporter 1 an Intestinal Uptake Transporter: Fact or Fiction?. Front. Pharmacol. 12: 648388. doi: 10.3389/fphar. 2021.648388
CN122005518A (zh) 神经肽y1受体拮抗剂在制备遗传性多囊肾病治疗药物中的应用
Zhang Development of cyclophilin inhibitors for the treatment of pancreatitis
Ting Pharmacokinetics and limited sampling strategies of mycophenolic acid in lung transplant recipients